218 related articles for article (PubMed ID: 38292233)
1. Tumor Immune Microenvironment as a New Therapeutic Target for Hepatocellular Carcinoma Development.
Kim E
Dev Reprod; 2023 Dec; 27(4):167-174. PubMed ID: 38292233
[TBL] [Abstract][Full Text] [Related]
2. Current insights into the hepatic microenvironment and advances in immunotherapy for hepatocellular carcinoma.
Zhao M; Huang H; He F; Fu X
Front Immunol; 2023; 14():1188277. PubMed ID: 37275909
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular Carcinoma Tumor Microenvironment and Its Implications in Terms of Anti-tumor Immunity: Future Perspectives for New Therapeutics.
Satilmis B; Sahin TT; Cicek E; Akbulut S; Yilmaz S
J Gastrointest Cancer; 2021 Dec; 52(4):1198-1205. PubMed ID: 34625923
[TBL] [Abstract][Full Text] [Related]
4. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
5. New Therapeutics for HCC: Does Tumor Immune Microenvironment Matter?
Khanam A; Kottilil S
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613878
[TBL] [Abstract][Full Text] [Related]
6. [Strategies and challenges of immunotherapy for hepatocellular carcinoma].
Zhang HH; Chen HS
Zhonghua Gan Zang Bing Za Zhi; 2020 Jun; 28(6):457-460. PubMed ID: 32660170
[TBL] [Abstract][Full Text] [Related]
7. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.
Liu Y; Xun Z; Ma K; Liang S; Li X; Zhou S; Sun L; Liu Y; Du Y; Guo X; Cui T; Zhou H; Wang J; Yin D; Song R; Zhang S; Cai W; Meng F; Guo H; Zhang B; Yang D; Bao R; Hu Q; Wang J; Ye Y; Liu L
J Hepatol; 2023 Apr; 78(4):770-782. PubMed ID: 36708811
[TBL] [Abstract][Full Text] [Related]
8. Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment.
Granito A; Muratori L; Lalanne C; Quarneti C; Ferri S; Guidi M; Lenzi M; Muratori P
World J Gastroenterol; 2021 Jun; 27(22):2994-3009. PubMed ID: 34168403
[TBL] [Abstract][Full Text] [Related]
9. Bibliometric study of immunotherapy for hepatocellular carcinoma.
Li Z; Zhang Y; Zhang B; Guo R; He M; Liu ZL; Yang L; Wang H
Front Immunol; 2023; 14():1210802. PubMed ID: 37600802
[TBL] [Abstract][Full Text] [Related]
10. Immune System and Hepatocellular Carcinoma (HCC): New Insights into HCC Progression.
Kotsari M; Dimopoulou V; Koskinas J; Armakolas A
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511228
[TBL] [Abstract][Full Text] [Related]
11. Tumor-Associated Macrophages in Hepatocellular Carcinoma: Friend or Foe?
Zhou D; Luan J; Huang C; Li J
Gut Liver; 2021 Jul; 15(4):500-516. PubMed ID: 33087588
[TBL] [Abstract][Full Text] [Related]
12. Role of exosomes in the development of the immune microenvironment in hepatocellular carcinoma.
Li T; Jiao J; Ke H; Ouyang W; Wang L; Pan J; Li X
Front Immunol; 2023; 14():1200201. PubMed ID: 37457718
[TBL] [Abstract][Full Text] [Related]
13. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
Gao S; Zhang L; Wang H
Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
[TBL] [Abstract][Full Text] [Related]
14. Immune landscape and immunotherapy of hepatocellular carcinoma: focus on innate and adaptive immune cells.
Gao X; Zuo S
Clin Exp Med; 2023 Oct; 23(6):1881-1899. PubMed ID: 36773210
[TBL] [Abstract][Full Text] [Related]
15. Idarubicin-loaded biodegradable microspheres enhance sensitivity to anti-PD1 immunotherapy in transcatheter arterial chemoembolization of hepatocellular carcinoma.
Zheng Z; Ma M; Han X; Li X; Huang J; Zhao Y; Liu H; Kang J; Kong X; Sun G; Sun G; Kong J; Tang W; Shao G; Xiong F; Song J
Acta Biomater; 2023 Feb; 157():337-351. PubMed ID: 36509402
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
[TBL] [Abstract][Full Text] [Related]
17. Obesity contributes to hepatocellular carcinoma development via immunosuppressive microenvironment remodeling.
Yang J; He J; Feng Y; Xiang M
Front Immunol; 2023; 14():1166440. PubMed ID: 37266440
[TBL] [Abstract][Full Text] [Related]
18. Personalized neoantigen vaccine combined with PD-1 blockade increases CD8
Chen H; Li Z; Qiu L; Dong X; Chen G; Shi Y; Cai L; Liu W; Ye H; Zhou Y; Ouyang J; Cai Z; Liu X
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36113894
[TBL] [Abstract][Full Text] [Related]
19. Immune cell infiltration and immunotherapy in hepatocellular carcinoma.
Jiang Y; Lin L; Lv H; Zhang H; Jiang L; Ma F; Wang Q; Ma X; Yu S
Math Biosci Eng; 2022 May; 19(7):7178-7200. PubMed ID: 35730302
[TBL] [Abstract][Full Text] [Related]
20. Molecular and immunological paradigms of hepatocellular carcinoma: Special reference to therapeutic approaches.
Kabashima A; Shimada S; Shimokawa M; Akiyama Y; Tanabe M; Tanaka S
J Hepatobiliary Pancreat Sci; 2021 Jan; 28(1):62-75. PubMed ID: 33259135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
